Recilisib is primarily investigated for its potential in mitigating the harmful effects of radiation exposure. It is being studied as a radioprotectant, particularly in scenarios where individuals may be exposed to high levels of ionizing radiation, such as during cancer radiotherapy or in the event of nuclear accidents. The compound aims to protect healthy tissues from radiation-induced damage, thereby reducing side effects and improving patient outcomes. Additionally, Recilisib is explored for its application in enhancing the safety and efficacy of radiation therapy in cancer treatment, allowing for higher doses of radiation to be targeted at tumors while sparing surrounding healthy tissues. Its potential use in emergency preparedness for radiation exposure incidents is also a significant area of research.